Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Knockdown of HEY1 in HCC cell line, Huh7

PROVIDER: PRJNA574563 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10193762_1.fastq.gz	Fastqsanger.gz
	SRR10193762_2.fastq.gz	Fastqsanger.gz
	SRR10193763_1.fastq.gz	Fastqsanger.gz
	SRR10193763_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Determine changes of lncRNAs expression in malignant hepatocytes

Project description:We performed a hybridization-based microarray analysis for lncRNA expression to understand the involvement of lncRNAs in HCC and to investigate differentially expressed lncRNAs in HCC, thereby characterizing their potential roles in tumor growth. The expression profiles of SMMC7721 HepG2 and Huh7 human HCC cell lines and the HL-7702 human immortalized normal hepatocyte cells were performed by the lncRNA microassay. SMMC7721, HepG2 and Huh7 human HCC cell lines were defined as the experimental group and HL-7702 cell line was used as the control.

2014-04-01 | E-GEOD-56384 | biostudies-arrayexpress

KCa3.1 depletion effect on hepatocellular carcinoma cell line Huh7

Project description:Analysis of Huh7 hepatocellular carcinoma (HCC) cells depleted for potassium channel KCa3.1, the intermediate conductance calcium-activated potassium channel. Result provide insight into the role of KCa3.1 in the carcinogenesis of HCC. We used microarrays to detail the gene expression differences between KCa3.1 knockdown and negative control in Huh7 HCC cells.

2018-06-23 | GSE116183 | GEO

Glucose deprivation effect on Hepatocellular carcinoma cell line: Huh-7

Project description:Analysis of Hepatocellular carcinoma (HCC) cell line - Huh7 deprived of glucose. Glucose restriction promotes a liver tumor-initating cell phenotype. Results provide insight into the molecular mechanism of glucose deprivation in HCC.

2024-06-17 | GSE152927 | GEO

Nascent proteome and glycoproteome reveal the inhibition role of ALG1 in hepatocellular carcinoma cell migration

Project description:(1) ALG1-related changes of the nascent proteome in Huh7 cell line (2) Knockdown of ALG1 inhibited the expression of glycosylated N-cadherin

2021-10-11 | PXD029045 |

Gene expression signatures for Nanog-positive and Nanog-negative hepatocellular carcinoma cells

Project description:Whole genome microarray expression profiling of HCC cell line (Huh7) and patients derive primary HCC cells (T1115 and T1224) expressing Nanog or not. Results provide insight into the role of Nanog in transcriptional regulation.

2014-11-13 | GSE33741 | GEO

Transcriptomics-based drug repurposing approach identifies novel drugs against sorafenib-resistant hepatocellular carcinoma

Project description:Hepatocellular carcinoma (HCC) is frequently diagnosed in patients with late-stage disease who are ineligible for curative surgical therapies. Furthermore, the majority of patients become resistant to sorafenib. Recently, computational methods for drug repurposing have shown great promise to accelerate the discovery of new uses for existing drugs. In order to identify novel drugs for use against sorafenib resistant (SR)-HCC, we employed a transcriptomics-based drug repurposing method termed connectivity mapping. We conducted a comprehensive analysis of available in vitro and in vivo gene signatures of (SR)-HCC, and generated our own in vitro model using the Huh7 HCC cell line. We compared coverage of SR-HCC gene signatures across seven patient-derived HCC gene expression datasets, and observed that patients harboring the Huh7 SR-HCC gene signature had significantly reduced survival. Utilizing the Huh7 SR-HCC gene signature, we applied connectivity mapping to drug-induced gene expression profiles (n= 3,740 drugs) in the HepG2 HCC cell line from the LINCS database in order to find drugs that could oppose sorafenib resistance. We validated the use of two non-receptor tyrosine kinase inhibitors, dasatinib and fostamatinib, to reduce viability of sorafenib-resistant HCC cells and confirmed up-regulated activity of Src family kinases, the targets of dasatinib, in our SR-HCC models. We prospectively validated predicted gene expression changes in fostamatinib treated Huh7-SR via RNA-seq analysis.

2019-09-01 | GSE113005 | GEO

Expression data comparing Huh7 control and CD47 knockdown cells

Project description:To identify candidate genes regulated by CD47 Affymetrix Human Genome U133 Plus GeneChip 2.0 HCC cell line Huh7 cells with or without CD47 repressed

2014-06-01 | E-GEOD-47563 | biostudies-arrayexpress

Investigation of downstream genes regulated by ACOT12 in HCC cells [Huh7]

Project description:Huh7 cell, a human hepatocellular carcinoma (HCC) cell line, was stably overexpressed with scramble shRNA or shRNA against ACOT12. These cells were then used for gene expression profiles analysis.

2019-01-01 | GSE111760 | GEO

Transcriptomic study of hepatocarcinoma cells exposed to sorafenib

Project description:sorafenib is the treatment of reference for hepatocellular carcinoma (HCC). We applied sorafenib on the human HCC cell line Huh7 and the subclone shRb, carrying a stable knock-down of the expression of the RB1 gene, a key regulator of liver carcinogenesis. Our aim was to better understand the physiologic and metabolic consequences of the exposure of HCC cells to sorafenib. We used microarrays to detail the global programme of gene expression at an early time point (9h) after exposure to sorafenib Whole-genome microarrays were used to study the transcriptome of Huh7 cells exposed to Sorafenib

2016-06-30 | E-GEOD-75620 | biostudies-arrayexpress

Expression data comparing Huh7 cells transduced with shRNA CD24 (knockdown) or non-target control

Project description:To identify CD24 signaling pathway Affymetrix Human Genome U133 Plus GeneChip 2.0 shRNA CD24 (knockdown) or non-target control (NTC) was stably transduced into Huh7 HCC cells by lentiviral approach

2012-01-01 | E-GEOD-28057 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data